SCOTTSDALE, Ariz., April 21, 2010 (GLOBE NEWSWIRE) -- Health Enhancement Products, Inc. (OTCBB:HEPI) has named Dr. Denis M. Callewaert its Chief Science Officer, effective today. Dr. Callewaert will chair the Science Advisory Board that now includes Donald Armstrong, PhD, DSc, professor emeritus SUNY – Buffalo and Visiting Professor, Showa University School of Medicine; Eric Holland, MD, PhD and vice-chair of Translational Research, Department of Neurosurgery at the Sloan-Kettering Institute; and Jack Vanden Heuvel, professor of Molecular Toxicology at Penn State University.
Dr. Callewaert holds a PhD in biochemistry and is professor emeritus at Oakland University, located in Rochester Hills, Michigan, where he also founded the university's Center for Biomedical Research and served as its executive director for nearly 20 years. In 1985, he founded Oxford Biomedical Research, an independent R&D laboratory providing life science tools to biomedical researchers worldwide. He has also been awarded over 40 NIH research and commercialization grants. Dr. Callewaert also founded Oxford Laboratories, which produced thyroid testing products for companion animals, and most recently, Wellness Indicators, Inc., a biotech firm that develops human metabolic tests.
"We're pleased to have attracted a scientist of Dr. Callewaert's standing," states John Gorman, Director of the company. "He's uniquely qualified to handle this job because it's positioned at the interface between science and commerce, a place that Dr. Callewaert finds both familiar and challenging." "Finding a qualified Chief Science Officer such as Dr. Callewaert was a necessary step for HEPI in moving the science forward. Under his direction HEPI will now begin the process to file for IND (Investigational New Drug) approval which once received allows HEPI to pursue its potential options in the pharmaceutical industry."
About Health Enhancement Products, Inc.
Health Enhancement Products, Inc. (OTCBB:HEPI) is a health & wellness company engaged in the development of products comprised of pure, all-natural compounds that can be used as a dietary supplement and food additive. The Company's product is ProAlgaZyme® (PAZ™) a liquid product drawn from living algae grown in purified water. The water in which the algae are grown is drawn off, filtered and bottled under the trademark ProAlgaZyme®.
Safe Harbor Statement
Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, and the company's ability to secure funding. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.
For more information, please visit www.heponline.com/" target="_top" rel="nofollow">http://www.heponline.com.